Zuclopenthixol decanoate depot injection

Four studies relating to zuclopenthixol decanoate were included. All compared zuclopenthixol decanoate with other depot preparations. Zuclopenthixol decanoate prevented or postponed relapses when compared to other depots ( NNT 8, CI 5-53). However, zuclopenthixol decanoate may induce more adverse effects (NNH 5, CI 3-31) although it decreases need for anticholinergic medication when compared to a group of other depot preparations ( NNT 9, CI 5-38). For the risk of leaving the study early, there was also a trend for benefit to those allocated to zuclopenthixol decanoate. None of the studies reported outcomes on service utilisation, costs, or quality of life.

Fluphenazine came into use in 1959. [6] The injectable form is on the World Health Organization's List of Essential Medicines , the most effective and safe medicines needed in a health system . [7] It is available as a generic medication . [1] In the United States the tablets costs between and USD per day for a typical dose. [1] The wholesale cost in the developing world of the long acting form is between and USD per injection as of 2014. [8] It was discontinued in Australia around mid 2017. [9]

Zuclopenthixol decanoate depot injection

zuclopenthixol decanoate depot injection

Media:

zuclopenthixol decanoate depot injectionzuclopenthixol decanoate depot injectionzuclopenthixol decanoate depot injectionzuclopenthixol decanoate depot injectionzuclopenthixol decanoate depot injection